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Abstract The signs and symptoms of ankylosing spondy-
litis (AS) respond inadequately to nonsteroidal antiinXam-
matory drugs, corticosteroids, and disease modifying
antirheumatic drugs in quite a number of patients. Tumor
necrosis factor inhibitors have demonstrated to be of value
in reducing AS disease activity in clinical trials. The
eYcacy and safety of both etanercept and inXiximab in
patients with ankylosing spondylitis were compared in a
2-year open label randomised study. Our results are consis-
tent with a signiWcant more rapid clinical improvement in
the inXiximab treated group. Treatment with both etaner-
cept and inXiximab at the end of the study was eVective,
safe, and well tolerated.
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InXiximab
Introduction
Ankylosing spondylitis (AS) is a debilitating disease pre-
dominantly aVecting the spine characterized by axial
skeletal ankylosis [1]. Therapeutic options for AS, such as
non-steroidal anti-inXammatory drugs (NSAIDs), oVer
temporary pain relief with little if any clinical beneWt on
spinal mobility, and disease modifying antirheumatic drugs
(DMARDs) do not appear to aVect the spinal involvement
of AS [2].
Tumor necrosis factor is a proinXammatory cytokine that
appears to have a key role in the pathogenesis of AS inXam-
mation [3]. Etanercept is a fully human recombinant pro-
tein, comprising two molecules of soluble TNF receptor
p75 and the crystallisable fragment component of immuno-
globulin G1, which speciWcally binds to and neutralizes
TNF-alpha. Several clinical studies have shown that etaner-
cept reduces disease activity in patients with spondyloarthr-
opathies, including reactive arthritis and AS [4–8]. Similar
results have been reported with inXiximab, a chimeric
monoclonal antibody against TNF [9–15]. The aim of the
present work was to compare the eYcacy and safety of both
etanercept and inXiximab in patients with ankylosing spon-
dylitis in a two-year open label randomised study.
Patients and methods
Fifty consecutive patients that fulWlled the modiWed New
York criteria for the diagnosis of AS [16] were enrolled in
the study. Patients had to be non responder to oral non-ste-
roidal anti-inXammatory drugs and naïve for DMARDs or
other TNF blocking agents. Patients with complete ankylo-
sis (fusion) of the spine were excluded. Approval from an
independent ethics committee was obtained, and all patients
provided written informed consent to participate. Patients
were randomised to receive alternatively etanercept or
inXiximab with a ratio of 1:1. EYcacy and safety evalua-
tions were performed at weeks 2, 4, 8, and 12 and then
every 3 months until 2 years. Criteria for inclusion were:
active disease for at least 3 months, a BASDAI >4 and a
VAS for spinal pain score >4.
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Patients received etanercept at a 50 mg dose delivered
subcutaneously weekly or inXiximab at 5 mg/kg at week 0,
2, 6 and every 6 weeks for a period of 102 weeks. The clin-
ical response to etanercept or inXiximab was evaluated on
the basis of response criteria recommended by the ASAS
Working Group [17]. An ASAS 20 and 40 responder was
deWned as a patient who showed at least 20 or 40%
improvement from baseline and had an absolute improve-
ment from baseline of at least 1 unit (on a scale of 0–10) in
at least 3 of the following 4 assessment domains: patient’s
global assessment, spinal pain, function according to the
Bath Ankylosing Spondylitis Functional Index (BASFI),
and morning stiVness (the average of the last 2 questions of
the BASDAI).
Disease activity was assessed bay the Bath Ankylosing
Spondylitis Activity Index (BASDAI). Functional impair-
ment was assessed by the ten item Bath Ankylosing Spon-
dylitis Functional Index (BASFI). The BASMI is an
aggregate score (ranging from 0 to 10) of patient mobility
assessments, including tragus-to-wall lumbar Xexion
(Schober test), cervical rotation, lumbar side Xexion, and
intermalleolar distance [18, 19]. Chest expansion is the
diVerence between the circumference of the chest in maxi-
mal inspiration and that in maximal expiration.
Patients were monitored for adverse events and abnor-
mal laboratory test results over the course of the study.
Vital signs were monitored, and standard hematology,
serum chemistry, and urine analysis tests were evaluated.
Statistics
To compare mean diVerences between time points (week 0
vs. week 12, week 54 and week 104), a unpaired t-test was
applied. In the case of skewed distributions [CRP and
erythrocyte sedimentation rate (ESR)], the corresponding
non-parametric test (Wilcoxon test) was used. McNemar
test was applied in the case of proportions.
Results
A total of 50 patients were enrolled in the study; 25 were
assigned to receive etanercept and 25 were assigned to
inXiximab. The average age of patients was 32.2 § 8 years.
39 patients were male (79%) and the duration of symptoms
was 15.6 § 8.7 years. The treatment groups had similar
baseline disease activity scores and demographic character-
istics (Table 1). No patients discontinued therapies.
Although the diVerence was not statistically signiWcant,
more inXiximab patients than etanercept patients responded
at the ASAS 20 level as early as week 2 but sustained
diVerences were not evident up to week 12. After 12 weeks,
19 of 25 patients (75%) in the inXiximab group were ASAS
20 responders compared with 15 of 25 patients (60%) in the
etanercept group (Fig. 1). On the 12th week, 55% of patient
treated with inXiximab and 43% of patients treated with
etanercept were at the ASAS 40 level (Fig. 1). At week 12
more inXiximab than etanercept treated patients achieved a
signiWcantly reduction of BASDAI (4.8 vs. 5.9; p < 0.005
and 3.5 vs. 5.6; p < 0.005) (Fig. 2), and of BASFI (3.5 vs.
5; p < 0.005) (Fig. 3). Acute phase reactants, BASMI, SP
and HAQ signiWcantly decreased in both group of patients
from baseline during the observation period without diVer-
ences between the two groups (not shown). Treatments
were generally well tolerated and adverse events were
mostly mild to moderate (Table 2). There were no discon-
tinuations for safety reasons. In particular, there was no
Table 1 Baseline characteris-
tics of patients Baseline characteristics Treatment groups p
InXiximab 
(n = 25)
Etanercept 
(n = 25)
Age (mean § SD) 31.9 § 9.2 32.6 § 6.8 NS
Sex, M/F 19/6 20/5 NS
Duration of AS, years (mean § SD) 15.4 § 10.6 15.7 § 6.5 NS
HLA-B27 positive (%) 23 (92) 24 (96) NS
BASDAI score, 0–10 (mean § SD) 6.5 § 1.2 6.6 § 1.1 NS
BASFI score, 0–10 (mean § SD) 6.1 § 0.9 6.5 § 1.1 NS
BASMI score, 0–10 (mean § SD) 3.7 § 1.6 3.9 § 1.7 NS
Chest expansion, cm (mean § SD) 2.9 § 0.8 3.1 § 0.9 NS
Spinal Pain, 0–10 (mean § SD) 6.0 § 1.5 6.3 § 1.2 NS
Patient’s global assessment, 0–10 VAS 6.4 § 1.4 6.7 § 1.4 NS
CRP level, mg/l (mean § SD) 25 § 12.1 22.9 § 10.5 NS
ESR mm/1 h (mean § SD) 32.1 § 14.6 29.6 § 13.7 NS
HAQ (mean § SD) 1.5 § 0.5 1.4 § 0.5 NS
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cases of opportunistic infections, tuberculosis, congestive
heart disease, demyelinating disorders, lupus-like syn-
dromes, and malignancy.
Discussion
TNF blocking agents are internationally considered to rep-
resent a major progress in the treatment of AS. Compara-
tive studies with etanercept and inXiximab treatments were
not yet published, however. A 50 mg dose of etanercept
delivered subcutaneously weekly and 6 weeks infusion of
inXiximab (5 mg/kg) produced rapid, signiWcant, and sus-
tained improvement in multiple clinical and laboratory
measures of AS. Although no signiWcant diVerences were
observed at the end of the study, our results are consistent
with a signiWcant more rapid clinical improvement in the
inXiximab treated group. At week 12 in fact more inXix-
imab than etanercept treated patients achieved a signiW-
cantly reduction of BASDAI and BASFI, and there were
also more responders in the inXiximab group at the ASAS
20 and ASAS 40 level.
In general, improvements with both therapies were
observed at 2 weeks and were sustained up to the end of
observation. The potential interest of our study was also
that patients enrolled in our study were outpatients that
have to be considered at community levels.
CRP levels and ESR values signiWcantly decreased and
spinal mobility, as measured by Schober’s test, signiW-
cantly improved in patients undergoing both treatments.
The results of this randomised study suggest that treatment
with both etanercept and inXiximab is eVective, safe, and
well tolerated in patients with AS. Patients with AS, in fact,
were treated continuously and we did not observed any
reduction in eYcacy with both treatments.
Fig. 1 ASAS 20 and ASAS 40 response during a 2-year follow up.
Circles indicate patients treated with inXiximab. Triangles indicate
patients treated with etanercept. Although morte inXiximab treated
patients reacted an ASAS 20–40 response at the 12th week, the diVer-
ence was not statistically signiWcant
Fig. 2 BASDAI levels in patients treated with inXiximab or etaner-
cept, at 12th week a signiWcant decrease of BASDAI was obtained in
patients treated with inXiximab (p < 0.005)
Fig. 3 BASFI levels in patients treated with inXiximab or etanercept,
at 12th week a signiWcant decrease of BASFI was obtained in patients
treated with inXiximab (p < 0.005)
Table 2 No (%) of adverse events (AE) through week 104
AE InXiximab 
n (%)
Etanercept 
n (%)
p
Injection site reactions 1 (4) 5 (25) <0.005
Infusion reactions
Headache 8 (32) 7 (28) NS
Diarrhea 2 (8) 1 (4) NS
Tachycardia 12 (48) 8 (32) NS
Hypertension 4 (16) 2 (8) NS
Abdominal pain 1 (4) 1 (4) NS
Uveitis 1 (4) 2 (8) NS
Optic neuritis 1 (4) 1 (4) NS
Arthralgia 4 (16) 3 (12) NS
Vertigo 1 (4) 2 (8) NS
Severe infections 2 (8) 1 (4) NS
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